ArticleCase reports in oncology
Novel Combination of Metronomic Cyclophosphamide and Darolutamide Induces Sustained Clinical Response in Heavily Treated Prostate Cancer with Prostate-Specific Membrane Antigen-Negative Liver Metastases and Rapid Disease Progression.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case of salvageSurgical neurology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Treatment options for refractory prostate-specific membrane antigen (PSMA)-negative liver metastases from metastatic castration-resistant prostate cancer (mCRPC) are limited and challenging. This case report presents our clinical observation of a sustained response to a novel combination of metronomic cyclophosphamide (mCyc) and darolutamide in a 65-year-old male with heavily treated PSMA-negative mCRPC with rapid disease progression. Case Presentation: The patient was initially diagnosed 4 years prior to our evaluation with metastatic prostate cancer and treated with androgen deprivation therapy with leuprolide, enzalutamide, and definitive external beam radiation therapy to the prostate and pelvic lymphadenopathy, along with stereotactic body radiation to oligometastatic bone disease. Upon progression to mCRPC, he received abiraterone with prednisone followed by docetaxel with prednisone, both of which resulted in temporary disease stabilization but eventual rapid progression with deterioration in performance status. Given the lack of effective, tolerable options, a combination of mCyc and darolutamide was initiated. The patient demonstrated an impressive clinical response, including significant radiographic response in liver metastatic disease, an 80% reduction in prostate-specific antigen levels, and improved quality of life with resolution of all cancer-related symptoms without significant treatment-related toxicities, with ongoing response. Conclusion: This report highlights the complex challenges of managing mCRPC with PSMA-negative liver metastases. mCyc with darolutamide may represent a valuable therapeutic option for elderly patients with multiple comorbidities who have exhausted standard treatment options. However, further research is needed to establish the efficacy and safety of this combination in broader populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.